Dabrafenib Mesylate(GSK-2118436B)- Pharmacodynamics & Bioactivity
Dabrafenib Mesylate is a salt form of Dabrafenib. Dabrafenib is an inhibitor of certain mutated forms of BRAF kinase, several of which may be associated with stimulating tumour growth.
Dec 13，2019 Inhibitors
Cabozantinib (XL184)- antitumour effects
Cabozantinib is a small molecule inhibitor of multiple tyrosine kinase receptors. In vitro, it has demonstrated inhibitory activity against RET, MET and VEGFR-2 and against the RET mutant M918T.
Dec 13，2019 Antineoplastic agents
MDV-3100 (Enzalutamide)- Pharmacodynamic Properties
MDV3100, known as Enzalutamide, is a second-generation androgen receptor (AR) signaling inhibitor. It is able to inhibit binding of androgens to the AR, AR nuclear translocation, and the association o
Dec 13，2019 Inhibitors
Dabigatran etexilate (BIBR-1048)- Pharmacology
Dabigatran etexilate (Pradaxa, BIBR 1048, Boehringer Ingelheim) is the prodrug of dabigatran (originally known as BIBR 953), a potent, nonpeptidic small molecule.
Dec 13，2019 Inhibitors
Larotrectinib (LOXO-101)- Pharmacodynamics
Larotrectinib (VITRAKVIR) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG.
Dec 13，2019 Inhibitors
AZD3759- preclinical and clinical studies
AZD3759 is a selective EGFR inhibitor that can fully penetrate the blood-brain barrier (BBB), with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue.
Dec 13，2019 Inhibitors
Neratinib- pharmacology
Neratinib is an oral pan HER inhibitor that irreversibly inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2, and HER4.
Dec 13，2019 Inhibitors
AP26113- Pharmacodynamics
Brigatinib (AP26113) is a tyrosine kinase inhibitor with in vitro activity against a number of kinases, including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), FLT-3, and also epidermal g
Dec 13，2019 Inhibitors
BIBW2992 Dimaleate - Pharmacodynamics
Afatinib dimaleate (Tovok; BIBW2992; Gilotrif) is a salt form of Afatinib. Afatinib is a second-generation, orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases.
Dec 13，2019 Inhibitors
Lenvatinib - pharmacodynamics
Lenvatinib (LenvimaTM) is a multitargeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors.
Dec 13，2019 Inhibitors